Amneal Pharmaceuticals (AMRX) Enterprise Value (2017 - 2025)
Historic Enterprise Value for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to -$133.5 million.
- Amneal Pharmaceuticals' Enterprise Value fell 84531.48% to -$133.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$133.5 million, marking a year-over-year decrease of 84531.48%. This contributed to the annual value of -$45.6 million for FY2024, which is 929.57% up from last year.
- As of Q3 2025, Amneal Pharmaceuticals' Enterprise Value stood at -$133.5 million, which was down 84531.48% from -$5.7 million recorded in Q2 2025.
- Over the past 5 years, Amneal Pharmaceuticals' Enterprise Value peaked at $13.4 million during Q1 2025, and registered a low of -$439.0 million during Q1 2021.
- In the last 5 years, Amneal Pharmaceuticals' Enterprise Value had a median value of -$65.0 million in 2022 and averaged -$106.6 million.
- Its Enterprise Value has fluctuated over the past 5 years, first crashed by 479279.45% in 2023, then soared by 257410.36% in 2025.
- Amneal Pharmaceuticals' Enterprise Value (Quarter) stood at -$230.9 million in 2021, then surged by 99.56% to -$1.0 million in 2022, then plummeted by 4792.79% to -$50.2 million in 2023, then rose by 9.3% to -$45.6 million in 2024, then tumbled by 192.84% to -$133.5 million in 2025.
- Its Enterprise Value stands at -$133.5 million for Q3 2025, versus -$5.7 million for Q2 2025 and $13.4 million for Q1 2025.